FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that the Company plans to release on Wednesday, December 13, 2006 interim results for the U.S. pilot clinical trial for the use of GEM OS1™ Bone Graft in foot and ankle fusion indications. The Company will host a conference call and audio webcast at 5:00 p.m. EST the same day. Dr. Samuel E. Lynch, president and CEO, members of the Company’s management team, and clinical investigators for BioMimetic’s U.S. pilot clinical trial, will host the call to discuss the study findings followed by a Q&A session.
